These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 14644892

  • 1. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P.
    Ann Intern Med; 2003 Dec 02; 139(11):901-6. PubMed ID: 14644892
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
    Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y.
    Hypertension; 2005 Feb 02; 45(2):198-202. PubMed ID: 15655123
    [Abstract] [Full Text] [Related]

  • 9. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
    Devereux RB, Dahlöf B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, LIFE Study Group.
    Ann Intern Med; 2003 Aug 05; 139(3):169-77. PubMed ID: 12899584
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.
    Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B.
    Kidney Int Suppl; 2004 Nov 05; (92):S56-8. PubMed ID: 15485419
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):705-11. PubMed ID: 15734614
    [Abstract] [Full Text] [Related]

  • 13. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
    Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y, LIFE substudy.
    J Hypertens; 2004 Sep 01; 22(9):1805-11. PubMed ID: 15311110
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H, Pedersen OL, Dahlöf B, Kjeldsen SE, Lindholm LH.
    Ugeskr Laeger; 2003 Jan 27; 165(5):456-9. PubMed ID: 12599843
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161
    [Abstract] [Full Text] [Related]

  • 20. Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
    Vishram JK, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Mancia G, Okin PM, Rothwell PM, Wachtell K, Olsen MH.
    J Hypertens; 2015 Dec 17; 33(12):2422-30. PubMed ID: 26378687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.